These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39206095)

  • 21. Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.
    Ben-Avi R; Itzhaki O; Simansky D; Zippel D; Markel G; Ben Nun A; Schachter J; Besser MJ
    J Immunother; 2016 Jun; 39(5):218-22. PubMed ID: 27163742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell receptor gene rearrangements and cytotoxic activities of clones isolated from tumour-infiltrating lymphocytes (TIL) from melanoma patients.
    Pandolfi F; Boyle LA; Trentin L; Oliva A; Kurnick JT
    Clin Exp Immunol; 1994 Jan; 95(1):141-7. PubMed ID: 8287599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoantigen-specific CD4
    Hall MS; Teer JK; Yu X; Branthoover H; Snedal S; Rodriguez-Valentin M; Nagle L; Scott E; Schachner B; Innamarato P; Hall AM; Blauvelt J; Rich CJ; Richards AD; Ceccarelli J; Langer TJ; Yoder SJ; Beatty MS; Cox CA; Messina JL; Abate-Daga D; Mule JJ; Mullinax JE; Sarnaik AA; Pilon-Thomas S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
    Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
    Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In situ sensory adaptation of tumor-infiltrating T lymphocytes to peptide-MHC levels elicits strong antitumor reactivity.
    Dorothée G; Vergnon I; El Hage F; Le Maux Chansac B; Ferrand V; Lécluse Y; Opolon P; Chouaib S; Bismuth G; Mami-Chouaib F
    J Immunol; 2005 Jun; 174(11):6888-97. PubMed ID: 15905531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
    Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction.
    Asselin-Paturel C; Megherat S; Vergnon I; Echchakir H; Dorothée G; Blesson S; Gay F; Mami-Chouaib F; Chouaib S
    Cancer; 2001 Jan; 91(1):113-22. PubMed ID: 11148567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
    Gervois N; Heuze F; Diez E; Jotereau F
    Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 31. The Outcome of
    Poschke IC; Hassel JC; Rodriguez-Ehrenfried A; Lindner KAM; Heras-Murillo I; Appel LM; Lehmann J; Lövgren T; Wickström SL; Lauenstein C; Roth J; König AK; Haanen JBAG; van den Berg J; Kiessling R; Bergmann F; Flossdorf M; Strobel O; Offringa R
    Clin Cancer Res; 2020 Aug; 26(16):4289-4301. PubMed ID: 32303540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
    Schiltz PM; Beutel LD; Nayak SK; Dillman RO
    J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
    Ham B; Kim SY; Kim YA; Han D; Park T; Cha S; Jung S; Kim JH; Park G; Gong G; Lee HJ; Shin J
    Br J Cancer; 2024 Jul; 131(1):196-204. PubMed ID: 38750113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
    Giatromanolaki A; Anestopoulos I; Panayiotidis MI; Mitrakas A; Pappa A; Koukourakis MI
    Anticancer Res; 2021 Aug; 41(8):3989-3995. PubMed ID: 34281863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas.
    Echchakir H; Asselin-Paturel C; Dorothee G; Vergnon I; Grunenwald D; Chouaib S; Mami-Chouaib F
    Int J Cancer; 1999 Apr; 81(2):205-13. PubMed ID: 10188720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.
    Kongkaew T; Thaiwong R; Tudsamran S; Sae-Jung T; Sengprasert P; Vasuratna A; Suppipat K; Reantragoon R
    J Immunol Methods; 2022 Apr; 503():113229. PubMed ID: 35101548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.